A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache
NCT ID: NCT00055484
Last Updated: 2015-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
204 participants
INTERVENTIONAL
2002-03-31
2003-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Serotonergic or monoaminergic agents such as methysergide, which have demonstrated high degrees of effectiveness;
2. Non-serotonergic drugs such as beta-blockers, tricyclic antidepressants, valproate; and
3. Drugs with lesser demonstrated effectiveness, such as selective serotonin reuptake inhibitors, calcium channel antagonists, and non-steroidal anti-inflammatory drugs.
The choice of treatment must be individualized, and is influenced by contraindications, potential side effects, the need to treat associated symptoms like tension-type headache and insomnia, and drug cost.
Anticonvulsants, such as valproate, have shown significant degrees of efficacy in migraine prophylaxis when used in low doses. Considering the differences in proposed mechanisms of action of these agents, it is likely that a novel anticonvulsant such as zonisamide may also be an effective prophylactic treatment for migraine.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
zonisamide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are men or women, between the ages of 18 and 65, inclusive.
* Satisfy diagnostic criteria for migraine headache, consistent with criteria described in Headache Classification Criteria.
* Have at least 4 migraine attacks per 28 days \[each attack separated by at least 48 hours\] prior to the Screening Visit and experience at least 4 migraine attacks during the Screen/Baseline Phase.
* Agree to not become pregnant during the study and agree to use an adequate method of birth control during the study such as an adequate barrier method, hormonal contraceptive, or surgical sterilization. All women of childbearing potential must have a negative pregnancy test before entering the study and during the study.
* Are able to swallow the capsules whole.
* Are willing and able to follow Investigator instructions and study procedures, complete the daily diary, and report adverse events.
EXCLUSION:
Subjects meeting any of the following criteria will not be eligible to participate in this study:
* Have required more than 3 different rescue medications for control of a single attack anytime within 3 months prior to the Screening Visit.
* Have cluster headache or chronic tension type headache and are unable to distinguish between their different types of headache.
* Have basilar or hemiplegic migraine.
* Have used triptans more than 3 times per week within 3 months prior to the Screening Visit.
* Have received botulinum toxin injection(s) within 3 months prior to the Screening Visit.
* Have taken any other prophylactic medications for migraine within 5 half-lives prior to the Baseline Visit.
* Are pregnant or lactating.
* Have a history or current diagnosis of psychiatric disorder likely to require pharmacological intervention (e.g., antidepressants, MAO inhibitors, antipsychotics, mood-stabilizers, anxiolytics) during the study.
* Have clinically unstable cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease.
* Have laboratory test results that, in the opinion of the Investigator, are clinically significant abnormalities.
* Require treatment with any medication (e.g., daily opioids, daily beta-blockers, daily non-steroidal anti-inflammatory drugs, carbonic anhydrase inhibitors, eletriptan) or herbal supplements (e.g., St. John's Wort, ginseng, ginkgo biloba, kava kava, melatonin, petadolex) that might interact adversely with, or obscure, the action of the study medication.
* Have received psychoactive medication (e.g., other anticonvulsant drugs, antidepressants, antipsychotics, anxiolytics, mood stabilizers) within 5 half-lives prior to the Baseline Visit.
* Have previously enrolled in this study or previously treated with zonisamide.
* Have previously failed an adequate trial of another antiepilepsy drug for the treatment of migraine.
* Have a history of allergy or hypersensitivity to zonisamide or other sulfonamides.
* Have a history of skin rash, without other diagnosis, associated with any medication or any medical condition.
* Have a history of nephrolithiasis.
* Have received an experimental drug or used an experimental device within 30 days of the Screening Visit.
* Have a history of drug or alcohol abuse within 12 months prior to the Screening Visit.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Elan Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Affiliated Research Center
Huntsville, Alabama, United States
University of South Alabama Medical Ctr Department of Neurology
Mobile, Alabama, United States
Valley Neurological Headache Clinic
Phoenix, Arizona, United States
The New England Center for Headache
Stamford, Connecticut, United States
Radiant Research
Overland Park, Kansas, United States
Michigan Head-Pain & Neurological Institute
Ann Arbor, Michigan, United States
Mercy Health Research
Chesterfield, Missouri, United States
Headache Care Center
Springfield, Missouri, United States
Neurological Associates of Tulsa
Tulsa, Oklahoma, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
MetaClin Research
Austin, Texas, United States
Houston Headache Clinic
Houston, Texas, United States
Radiant Research
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AN46046-228
Identifier Type: -
Identifier Source: org_study_id